Logo for University of Iowa Health Care This logo represents the University of Iowa Health Care

New Funding Awards

Includes new, competitive renewal and supplemental awards.

See additional awards here: https://medicine.uiowa.edu/research/scientific-impact/deans-list-new-funding-awards

September 2021

PI Sponsor Title
Dale Abel, Long-Sheng Song NIH R01 - 4 years Molecular Determinants of MG53 in heart structure and function
Muhammad Furqan PPD Investigator Services, LLC A Randomized, Parallel-Group Treamtent, Phase 2/3, Open-Label, 3-Arm Study Comparing Efficacy of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to  Docetaxel Alone in Male and Female Participants Aged 18 years and Older with Advanced Non-Sm
Duane Hall NIH R01 - 4 years ERK1/2-Integrin Signaling in Desmosome-Dyad Crosstalk
Mohammed Milhem TopAlliance Biosciences, Inc A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects with Advanced Solid Malignancies including Lymphoma
Sidakpal Panaich Edwards Lifesciences, LLC PASCAL CLASP IID/IIF Pivotal Clinical Trial
Huy Tran Alnylam Pharmaceuticals, Inc A Phase 1, Randomized, Double-Blind, Placebo- Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients with Nonalcoholic Steat

August 2021

PI Sponsor Title
Alejandro Comellas Gala Therapeutics, Inc A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients with COPD
Rohan Garje Immunomedics, Inc A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
Pashtoon Kasi Seagen, Inc MOUNTAINEER-02: Tucatinib, trastuzumab, ramucirumab, and paclitaxel versus paclitaxel and ramucirumab in previously treated HER2+ gastroesophageal cancer
Sneha Phadke Genentech, Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk fo Recurrence
Praveen Vikas Sanofi US Services, Inc A Randomized, Multicenter, Double-blind, Phase 3 Study of SAR439859 plus Palbociclib Versus Letrozole plus Palbociclib for the Treatment of Patients with ER (+), HER2 (-) Breast Cancer who have not Received any Prior Systemic Anti-Cancer Treatment for Adv
Patricia Winokur Pfizer, Inc A Phase 3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of Respiratory Syncytial Virus (RSV) Prefusi on F Subunit Vaccine in Adults
Yousef Zakharia Astellas Pharmac, Inc A Phase 1/2, Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Known to Express WT1 Antigen
Yousef Zakharia Seattle Genetics, Inc. A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

July 2021

PI Sponsor Title
Muhammad Furqan PPD Investigator Services, LLC A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinu
Nabeel Hamzeh Genentech, Inc A Phase III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis
Sidakpal Panaich Edwards Lifesciences, LLC Edwards PASCAL CLASP II TR Pivotal Clinical Trial
Rasna Sabharwal NIH 1 R21 - 2 years RAS-Driven Central Inflammation and Cognitive Decline with Aging.
Patricia Winokur Pfizer, Inc A Study to Evaluate Additional Dose(s) of BNT162b2 in Healthy Individuals  Previously Vaccinated With BNT162b2

June 2021

PI Sponsor Title
Linda Cadaret Endotronix, Inc PROACTIVE-HF
Chandrikha Chandrasekharan Genentech, Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Rebecca Dodd DoD, CDMRP - 3 years NF200067 - Targeting a pro-tumorigenic immunosuppressive loop in MPNST            
David Hughes NIH K01 - 5 years The role of Fbxl22 in the regulation of skeletal muscle mass
Pashtoon Kasi Elicio Therapeutics, Inc First in Human Phase 1 /2 Trial of ELI-002 Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Steven Lentz NIH T32 - 5 years Medical Scientist Training Program
Mohammed Milhem Checkmate Pharmaceuticals A Randomized, Open-Label, Active-Control, Phase 2/3 Study of First-Line Intratumoral CMP-001 in Combination with Intravenous Nivolumab Compared to Monotherapy in Subjects with Unresectable or Metastatic Melanoma
Jack Stapleton Iowa Department of Public Health HIV Core and Medical Support Services
Michael Tomasson Pfizer, Inc An Open-Label, Multicenter, Non-Randomized Phase 2 Study of PF 06863135 Monotherapy in Participants with Multiple Myeloma who are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and One Anti-CD38 Antibody
Mary Wilson NIH T32 - 5 years Training in Mechanisms of Parasitism (Competitive Renewal)

May 2021

PI Sponsor Title
Dale Abel, Val Sheffield NIH R01 - 5 years Modulating ROS by electromagnetic fields to treat Type 2 Diabetes
Chad Grueter NIH R03 - 1 year Cdk19-dependent transcriptional mechanisms in cardiac hypertrophy
Loreen Herwaldt CDC U54 - 5 years Infection Prevention and Antimicrobial Stewardship: Minding the Gaps: The Iowa Prevention Epicenter
Douglas Laux Checkmate Pharmaceuticals Intratumoral CMp-001 In Combo w/ Intravenous Pembrolizumab in Subjects with Head and Neck Squamous Cell Carcinoma
Antonio Sanchez Boehringer Ingelheim Pharmaceuticals, Inc A trial to evaluate efficacy, safety and tolerability of multiple subcutaneous doses of BI 456906 in patients with NASH and fibrosis
Jack Stapleton AbbVie, Inc Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ABBV-382 in Persons Living with HIV-1 (PLWH)
Tomohiro Tanaka GlaxoSmithKline LLC Sequential GSK32288363 and Peginterferon Treatment in Participants with Chronic Hepatitis B Virus (B-Together)
Anne-Sophie Wattiez Schedule 1 Therapeutics Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics

April 2021

PI Sponsor Title
Joseph Dillon, Yusuf Menda ITM Solucin GmbH Peptide Receptor Radionuclide Therapy with 177 Lu-Edotreotide Compared to Targeted Molecular Therapy
Mary Beth Fasano Benaroya Research Institute at Virginia Mason Systemic Allergic Reactions to SARS-CoV-2 Vaccination
Barcey Thurston Levy University of Massachusetts Medical School RADxAcceleRATeD study (Rapid Assessment of Technology for SARS-CoV-2 Detection)
Mohammed Milhem Checkmate Pharmaceuticals Intratumoral CMP-001 In Combo w/ Intravenous Nivolumab in Unresectable or Metastic Melanoma
Ernesto Ruiz Duque Alnylam Pharmaceuticals, Inc APOLLO-B: A Study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Michael Shy Charcot-Marie-Tooth Association CMT1X Biomarkers and Outcomes Measures
Grerk Sutamtewagul Novartis Pharmaceuticals Corporation Azacitidine with or without MBG453 for patients with Myelodysplastic syndrome (MDS)
George Weiner NIH P30 - 5 years Cancer Center Support Grant (CCSG) (Competitive Renewal)
Yousef Zakharia Incyte Biosciences International S.a.r.l. INCMGA00012, INCAGN02385, and INCAGN02390 in Participants with Select Advanced Malignancies

March 2021

PI Sponsor Title
Sabarish Ayyappan Genmab US Inc A Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Sabarish Ayyappan Regeneron Pharmaceuticals, Inc A study to assess the anti-tumor activity and safety of regn1979, an anti-cd20 x anti-cd3 bispecific antibody, in patients with relapsed or refractory b-cell non-Hodgkin lymphoma
Linda Cadaret Gossamer Bio, Inc Evaluating the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Muhammad Furqan Inhibrx, Inc A Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors
Prajwal Gurung NIH R01 - 5 years Implicating a previously unknown Dectin1-RIPK2-CARD9 signaling in providing resistance against Leishmania major infection
Varun Monga Pfizer, Inc A trial evaluating pharmacokinetics, safety and efficacy of pf 07284890 (arry 461) in participants with BRAF v600 mutant solid tumors with and without brain involvement
Philip Polgreen NIH R01 - 5 years Estimating the risk for and severity of respiratory infections attributable to CFTR hterozygosity
     

February 2021

PI Sponsor Title
Douglas Laux Replimune, Inc Cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaeneous squamous cell carcinoma
Varun Monga Medical College of Wisconsin Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as having CDK Pathway Alteration (BOAST)
Muhammad Furqan Hoosier Cancer Research Network, Inc Chemo-immunotherapy Followed by Combo of Durvalumab and ATRi in Treatment Naïve Patients with Extensive Stage Small Cell Lung Cancer
Muhammad Furqan Bristol-Myers Squibb Company First-in-human of BMS-986258 Alone and in Combo with Nivolumab in Advanced Tumors
Muhammad Furqan Aprea Therapeutics APR-246 in Combination with Pembrolizumab in Subjects with Solid Tumor Malignancies
Pat Winokur Sanofi Pasteur, Inc Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older

January 2021

PI Sponsor Title
Alejandro Comellas Regeneron Pharmaceuticals, Inc The virologic efficacy of REGN10933+REGN10987 across different dose regimens in outpatients with SARS-CoV-2
Muhammad Furqan PPD Investigator Services, LLC Autologous T-Cells expressing enhanced TCRs specific for NY-ESO-1/LAGE-1a alone or in combo with pembrolizumab
Margarida Magalhaes-Silverman Marker Therapeutics, Inc Donor-derived multi-tumor-associated antigen-specific T Cells administered to patients with AML following hematopoietic stem cell transplantation
Philip Polgreen University of Maryland Gathering new contact network data to inform interventions designed to Decrease the Spread of COVID-19
Antonio Sanchez Merck Sharp & Dohme Corp Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis
Shunguang Wei NIH R01 - 4 years Novel Role of Interleukin-17 in Sympathetic Activation in Heart Failure

 


 

See additional awards here: https://medicine.uiowa.edu/research/scientific-impact/deans-list-new-funding-awards